全文获取类型
收费全文 | 894509篇 |
免费 | 75316篇 |
国内免费 | 4117篇 |
专业分类
耳鼻咽喉 | 13165篇 |
儿科学 | 25006篇 |
妇产科学 | 25379篇 |
基础医学 | 128285篇 |
口腔科学 | 25928篇 |
临床医学 | 79134篇 |
内科学 | 169860篇 |
皮肤病学 | 17722篇 |
神经病学 | 72061篇 |
特种医学 | 36839篇 |
外国民族医学 | 178篇 |
外科学 | 139531篇 |
综合类 | 29730篇 |
现状与发展 | 6篇 |
一般理论 | 266篇 |
预防医学 | 69008篇 |
眼科学 | 21406篇 |
药学 | 68482篇 |
18篇 | |
中国医学 | 3975篇 |
肿瘤学 | 47963篇 |
出版年
2018年 | 8636篇 |
2016年 | 7881篇 |
2015年 | 9553篇 |
2014年 | 13223篇 |
2013年 | 18843篇 |
2012年 | 25531篇 |
2011年 | 26719篇 |
2010年 | 15799篇 |
2009年 | 14563篇 |
2008年 | 24292篇 |
2007年 | 26318篇 |
2006年 | 26059篇 |
2005年 | 25654篇 |
2004年 | 24821篇 |
2003年 | 24055篇 |
2002年 | 22982篇 |
2001年 | 36661篇 |
2000年 | 37123篇 |
1999年 | 31428篇 |
1998年 | 9554篇 |
1997年 | 8869篇 |
1996年 | 8720篇 |
1995年 | 8206篇 |
1994年 | 7911篇 |
1992年 | 26785篇 |
1991年 | 26228篇 |
1990年 | 25736篇 |
1989年 | 24765篇 |
1988年 | 23293篇 |
1987年 | 22943篇 |
1986年 | 21798篇 |
1985年 | 21135篇 |
1984年 | 16403篇 |
1983年 | 14004篇 |
1982年 | 8865篇 |
1981年 | 8218篇 |
1980年 | 7685篇 |
1979年 | 16752篇 |
1978年 | 12119篇 |
1977年 | 10185篇 |
1976年 | 9332篇 |
1975年 | 10151篇 |
1974年 | 12646篇 |
1973年 | 12141篇 |
1972年 | 11544篇 |
1971年 | 10687篇 |
1970年 | 10219篇 |
1969年 | 9913篇 |
1968年 | 8902篇 |
1967年 | 8233篇 |
排序方式: 共有10000条查询结果,搜索用时 46 毫秒
61.
62.
63.
William G. Breen Krishan R. Jethwa Nathan Y. Yu Grant M. Spears William S. Harmsen Robert C. Miller Jonathan B. Ashman William G. Rule Terence T. Sio Michelle A. Neben-Wittich Michael G. Haddock Amit Mahipal Mark J. Truty Christopher L. Hallemeier Kenneth W. Merrell 《Practical radiation oncology》2021,11(1):e63-e69
PurposeOur purpose was to determine the effect of chemoradiotherapy (CRT) on patient-reported quality of life (QOL) for patients with intact pancreas cancer.Methods and MaterialsWe reviewed a prospective QOL registry for patients with intact, clinically localized pancreatic ductal adenocarcinoma treated with CRT between June 2015 and November 2018. QOL was assessed pre-CRT (immediately before CRT, after neoadjuvant chemotherapy) and at the completion of CRT with the Functional Assessment of Cancer Therapy-Hepatobiliary (FACT-Hep) and its component parts: FACT-General (FACT-G) and hepatobiliary cancer subscore (HCS). A minimally important difference from pre-CRT was defined as ≥ 6, 5, and 8 points for FACT-G, HCS, and FACT-Hep, respectively.ResultsOf 157 patients who underwent CRT, 100 completed both pre- and post-CRT surveys and were included in the primary analysis. Median age at diagnosis was 65 years (range, 23-90). National Comprehensive Cancer Network resectability status was resectable (3%), borderline resectable (40%), or locally advanced (57%). Folinic acid, 5-fluorouracil, irinotecan, and oxaliplatin (FOLFIRINOX) (75%) or gemcitabine and nab-paclitaxel (42%) were given for a median of 6 cycles (range, 0-42) before CRT. Radiation therapy techniques included 3-dimensional conformal (22%), intensity modulated photon (55%), and intensity modulated proton (23%) radiation therapy to a median dose of 50 Gy (range, 36-62.5). Concurrent chemotherapy was most commonly capecitabine (82%). Sixty-three patients (63%) had surgery after CRT. The mean decline in FACT-G, HCS subscale, and FACT-Hep from pre- to post-CRT was 3.5 (standard deviation [SD], 13.7), 1.7 (SD 7.8), and 5.2 (SD 19.4), respectively. Each of these changes were statistically significant, but did not meet the minimally important difference threshold. Pancreatic head tumor location was associated with decline in FACT-Hep. Nausea was the toxicity with the greatest increase from pre- to post-CRT by both physician-assessment and patient-reported QOL.ConclusionsFor patients with intact pancreatic adenocarcinoma, modern CRT is well tolerated with minimal decline in QOL during treatment. 相似文献
64.
The retroviral protease of human immunodeficiency virus (HIV) is an excellent target for antiviral inhibitors for treating HIV/AIDS. Despite the efficacy of therapy, current efforts to control the disease are undermined by the growing threat posed by drug resistance. This review covers the historical background of studies on the structure and function of HIV protease, the subsequent development of antiviral inhibitors, and recent studies on drug-resistant protease variants. We highlight the important contributions of Dr. Stephen Oroszlan to fundamental knowledge about the function of the HIV protease and other retroviral proteases. These studies, along with those of his colleagues, laid the foundations for the design of clinical inhibitors of HIV protease. The drug-resistant protease variants also provide an excellent model for investigating the molecular mechanisms and evolution of resistance. 相似文献
65.
目的 探讨扶正消瘤颗粒对原发性肝癌血清中血管内皮生长因子(Vascular endothelial growth factor,VEGF)和缺氧诱导因子-1α(Hypoxia inducible factor-1α,HIF-1α)表达的影响及临床意义。方法 选择符合纳入标准的原发性肝癌患者66例,按1∶1随机分试验组和对照组。观察治疗过程中两组VEGF、HIF-1α水平的变化及对患者临床疗效指标的影响。结果 (1)在性别、年龄、合并乙型肝炎、Child-Pugh分级、AFP值、临床分期方面,试验组和对照组差异无统计学意义(P > 0.05)。(2)肝癌患者在治疗各时间节点的VEGF和HIF-1α表达水平呈线性正相关(r = 0.829,P < 0.001)。(3)VEGF浓度在经导管动脉化疗栓塞术(Transcatheter arterial chemoembolization,TACE)后3月降至术前水平(P > 0.05),HIF-1α在TACE后3月仍高于术前(P < 0.05)。(4)扶正消瘤颗粒可降低HIF-1α水平,下调VEGF的表达。(5)扶正消瘤颗粒可减少TACE序贯RFA治疗后的不良反应,提高患者的生活质量(P < 0.05)。(6)血清中VEGF水平与生活质量无明显相关性(P > 0.05,r = 0.251),HIF-1α水平与生活质量存在正相关性(P < 0.05,r = 0.450)。结论 扶正消瘤颗粒可明显改善TACE序贯RFA治疗后患者生活质量,降低HIF-1α水平,下调VEGF的表达,抑制肿瘤血管生成。 相似文献
66.
67.
68.
69.